Dr. Amir N. Rezk, MD

Dr. Rezk practices at Digestive Disease Associates of York Coutny PA in Rock Hill, South Carolina.

Dr. Rezk's NPI, 1558626234, was assigned on July 9, 2012. Dr. Rezk holds South Carolina license MD51882.

Dr. Rezk's primary practice is Digestive Disease Associates of York Coutny PA, at 170 Amendment Ave, Rock Hill, SC 29732 in York County. The practice phone is (803) 324-7607.

Dr. Rezk's primary practice is Digestive Disease Associates of York Coutny PA in Rock Hill, South Carolina. Dr. Rezk is also affiliated with Rock Hill Hospital - Piedmont Medical Network. The medical group on file is Digestive Disease Associates of York County. Dmand AI also links Dr. Rezk to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rezk practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Rezk's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dr. Rezk is licensed in South Carolina.

CMS data shows 677 Medicare services from Dr. Rezk across 14 procedure codes in 2024, for 299 Medicare patients. Medicare paid $67,246 for them.

CMS counts 299 Medicare patients who saw Dr. Rezk in 2024. The largest group is 65 to 74, with 149 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 9% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rezk's median patient age at 58, with 55% women.

In 2024, Dr. Rezk wrote 224 Medicare Part D claims for 91 patients. 73% of them were for generic drugs. CMS names the drug for 150 of them, across 4 drugs with 11 or more claims each, at $827,519 in total drug cost. In 2023, CMS named 96 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Rezk for performance year 2024, reported as part of a group. Dr. Rezk accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 133 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Rezk, more than 82% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Rezk in 2016. Dr. Rezk's most frequent co-author is Michael J. Komar, MD.

Dmand AI links Dr. Rezk to 1 clinical trial. Conditions studied include Clostridium Infections and Gram-Positive Bacterial Infections.

CMS Open Payments shows 60 general payments to Dr. Rezk from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $7,080.